AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Bausch Health Companies I... (BHC)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

6.33

-0.12 (-1.86%)

At close: Feb 10, 2025, 3:59 PM

6.32

-0.16%

After-hours Feb 10, 2025, 07:00 PM EST

undefined% (undefined)

Bid	6.12
Market Cap	2.33B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.48
PE Ratio (ttm)	-13.19
Forward PE	n/a
Analyst	Hold

Ask	6.7
Volume	1,322,573
Avg. Volume (20D)	2,138,203
Open	6.43
Previous Close	6.45
Day's Range	6.19 - 6.45
52-Week Range	3.96 - 11.46
Beta	undefined

About BHC

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Mar 29, 1994

Employees 20,270

Stock Exchange NYSE

Ticker Symbol BHC

Website https://www.bauschhealth.com

Analyst Forecast

According to 5 analyst ratings, the average rating for BHC stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 26.38% from the latest price.

Buy 0.00%

Hold 80.00%

Sell 20.00%

Stock Forecasts

Next Earnings Release

Bausch Health Companies Inc. is scheduled to release its earnings on Feb 19, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 days ago

-10.9%

Bausch Health shares are trading lower after the c... Unlock content with Pro Subscription

3 months ago

+6.3%

Bausch Health Companies shares are trading higher after RBC Capital raised its price target on the stock from $10 to $11.

News

1 day ago · accessnewswire.com

Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program

Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESS Newswire / February 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology...

5 days ago · reuters.com

Contact lens maker Bausch + Lomb rules out take-private deal

Bausch + Lomb will not be taken private at this time, the contact lens maker said on Thursday.

5 days ago · accessnewswire.com

Bausch Health Provides Update on Strategic Alternatives

LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives throu...

2 weeks ago · accessnewswire.com

Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025

LAVAL, QC / ACCESS Newswire / January 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, Febr...

2 weeks ago · businesswire.com

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarte...

3 weeks ago · accessnewswire.com

Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program

LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for...

3 weeks ago · zacks.com

Wall Street Analysts See a 25.5% Upside in Bausch (BHC): Can the Stock Really Move This High?

The mean of analysts' price targets for Bausch (BHC) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i...

3 weeks ago · youtube.com

Bausch + Lomb CEO on the negative impact of screen time on eye health

Brent Saunders, Bausch and Lomb CEO, discusses how too much screen time can have a negative impact on vision.

3 weeks ago · youtube.com

Bausch and Lomb CEO: Right on track with our important initiatives

Brent Saunders, Bausch and Lomb CEO, joins 'Money Movers' to discuss how Saunders has changed the portfolio in his time as chief executive, what the growth is like for Bausch and Lomb, and much more.

4 weeks ago · businesswire.com

Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate h...

Load More News